Novel Flow Cytometry-Based Method for Detection of Anti-HLA Complement Activating Donor-Specific Antibodies in Renal Transplant Recipients and Its Comparison With Other Conventional Detection Methods

Rani, Lekha; Singh, Heera; Saikia, Biman; Aggarwal, Ritu; Kumar, Yashwant; Kumar, Mahendra; Chhabra, Seema; Kumar, Manoj; Kumar, Bhuvnesh; Kumar, Vinkesh; Das, Prabir; Sharma, Ashish; Ramchandran, Raja; Kohli, Harbir Singh; Minz, Ranjana Walker

doi:10.1016/j.transproceed.2022.11.007

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Historically, immunological risk assessment in solid organ transplantation relied on complement-dependent cytotoxicity crossmatch tests (CDC) and later incorporated more sensitive flow cytometry crossmatching assays (4). Currently, the evaluation of humoral immunity, driven by antigen-specific B cells, primarily involves detecting and characterizing HLA antibodies in recipient serum using solid-phase technology such as Luminex SAB assays (5,6).…”

Section: Introductionmentioning

confidence: 99%

Memory B-cell derived donor-specific antibodies do not predict outcome in sensitized kidney transplant recipients: a retrospective single-center study

Altulea,

van den Born,

Diepstra

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundRepeated exposure to sensitizing events can activate HLA-specific memory B cells, leading to the production of donor-specific memory B cell antibodies (DSAm) that pose a risk for antibody-mediated rejection (ABMR) in kidney transplant recipients (KTRs). This single-center retrospective study aimed to identify DSAm and assess their association with outcomes in a cohort of KTRs with pretransplant serum donor-specific antibodies (DSA).MethodsWe polyclonally activated pretransplant peripheral blood mononuclear cells (PBMCs) from 60 KTRs in vitro, isolated and quantified IgG from the culture supernatant using ELISA, and analyzed the HLA antibodies of eluates with single antigen bead (SAB) assays, comparing them to the donor HLA typing for potential DSAm. Biopsies from 41 KTRs were evaluated for rejection based on BANFF 2019 criteria.ResultsAt transplantation, a total of 37 DSAm were detected in 26 of 60 patients (43%), of which 13 (35%) were found to be undetectable in serum. No significant association was found between pretransplant DSAm and ABMR (P=0.53). Similar results were observed in a Kaplan–Meier analysis for ABMR within the first year posttransplant (P=0.29). Additionally, MFI levels of DSAm showed no significant association with ABMR (P=0.28).ConclusionThis study suggests no significant association between DSAm and biopsy-proven clinical ABMR. Further prospective research is needed to determine whether assessing DSAm could enhance existing immunological risk assessment methods for monitoring KTRs, particularly in non-sensitized KTRs.

show abstract

Section: Introductionmentioning

confidence: 99%